EDIT
Price
$1.91
Change
+$0.11 (+6.11%)
Updated
Jun 6 closing price
Capitalization
150.68M
52 days until earnings call
SLDB
Price
$4.54
Change
+$0.29 (+6.82%)
Updated
Jun 6 closing price
Capitalization
329.44M
Interact to see
Advertisement

EDIT vs SLDB

Header iconEDIT vs SLDB Comparison
Open Charts EDIT vs SLDBBanner chart's image
Editas Medicine
Price$1.91
Change+$0.11 (+6.11%)
Volume$2.45M
Capitalization150.68M
Solid Biosciences
Price$4.54
Change+$0.29 (+6.82%)
Volume$1.61M
Capitalization329.44M
EDIT vs SLDB Comparison Chart
Loading...
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLDB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EDIT vs. SLDB commentary
Jun 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a Buy and SLDB is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 08, 2025
Stock price -- (EDIT: $1.87 vs. SLDB: $3.26)
Brand notoriety: EDIT and SLDB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EDIT: 144% vs. SLDB: 75%
Market capitalization -- EDIT: $150.68M vs. SLDB: $329.44M
EDIT [@Biotechnology] is valued at $150.68M. SLDB’s [@Biotechnology] market capitalization is $329.44M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EDIT’s FA Score shows that 0 FA rating(s) are green whileSLDB’s FA Score has 2 green FA rating(s).

  • EDIT’s FA Score: 0 green, 5 red.
  • SLDB’s FA Score: 2 green, 3 red.
According to our system of comparison, SLDB is a better buy in the long-term than EDIT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EDIT’s TA Score shows that 6 TA indicator(s) are bullish while SLDB’s TA Score has 3 bullish TA indicator(s).

  • EDIT’s TA Score: 6 bullish, 4 bearish.
  • SLDB’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, EDIT is a better buy in the short-term than SLDB.

Price Growth

EDIT (@Biotechnology) experienced а +24.67% price change this week, while SLDB (@Biotechnology) price change was +20.74% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.11%. For the same industry, the average monthly price growth was +10.01%, and the average quarterly price growth was -2.16%.

Reported Earning Dates

EDIT is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+4.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SLDB($329M) has a higher market cap than EDIT($151M). EDIT YTD gains are higher at: 47.244 vs. SLDB (-18.500). SLDB has higher annual earnings (EBITDA): -121.9M vs. EDIT (-233.11M). EDIT has more cash in the bank: 270M vs. SLDB (149M). SLDB has less debt than EDIT: SLDB (24.2M) vs EDIT (35M). EDIT has higher revenues than SLDB: EDIT (32.3M) vs SLDB (0).
EDITSLDBEDIT / SLDB
Capitalization151M329M46%
EBITDA-233.11M-121.9M191%
Gain YTD47.244-18.500-255%
P/E RatioN/AN/A-
Revenue32.3M0-
Total Cash270M149M181%
Total Debt35M24.2M145%
FUNDAMENTALS RATINGS
EDIT vs SLDB: Fundamental Ratings
EDIT
SLDB
OUTLOOK RATING
1..100
2111
VALUATION
overvalued / fair valued / undervalued
1..100
36
Fair valued
20
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
6491
P/E GROWTH RATING
1..100
1002
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SLDB's Valuation (20) in the Biotechnology industry is in the same range as EDIT (36). This means that SLDB’s stock grew similarly to EDIT’s over the last 12 months.

SLDB's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as EDIT (100). This means that SLDB’s stock grew similarly to EDIT’s over the last 12 months.

SLDB's SMR Rating (98) in the Biotechnology industry is in the same range as EDIT (98). This means that SLDB’s stock grew similarly to EDIT’s over the last 12 months.

EDIT's Price Growth Rating (64) in the Biotechnology industry is in the same range as SLDB (91). This means that EDIT’s stock grew similarly to SLDB’s over the last 12 months.

SLDB's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for EDIT (100). This means that SLDB’s stock grew significantly faster than EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EDITSLDB
RSI
ODDS (%)
Bearish Trend 12 days ago
88%
N/A
Stochastic
ODDS (%)
Bearish Trend 12 days ago
85%
Bearish Trend 12 days ago
88%
Momentum
ODDS (%)
Bullish Trend 12 days ago
79%
Bullish Trend 12 days ago
80%
MACD
ODDS (%)
Bullish Trend 12 days ago
74%
Bullish Trend 12 days ago
75%
TrendWeek
ODDS (%)
Bullish Trend 12 days ago
78%
Bullish Trend 12 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 12 days ago
77%
Bearish Trend 12 days ago
90%
Advances
ODDS (%)
Bullish Trend 12 days ago
77%
Bullish Trend 12 days ago
79%
Declines
ODDS (%)
Bearish Trend 26 days ago
90%
Bearish Trend 26 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 12 days ago
88%
Bearish Trend 12 days ago
89%
Aroon
ODDS (%)
Bullish Trend 12 days ago
74%
Bearish Trend 12 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLDB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL200.420.21
+0.10%
Apple
SPY587.73-3.42
-0.58%
SPDR® S&P 500® ETF
BTC.X107802.330000-1192.312500
-1.09%
Bitcoin cryptocurrency
TSLA356.90-5.99
-1.65%
Tesla
GME31.21-3.80
-10.85%
GameStop Corp

EDIT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EDIT has been loosely correlated with CRSP. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if EDIT jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDIT
1D Price
Change %
EDIT100%
+13.33%
CRSP - EDIT
54%
Loosely correlated
-0.92%
NTLA - EDIT
50%
Loosely correlated
+3.59%
PRME - EDIT
49%
Loosely correlated
N/A
ABCL - EDIT
47%
Loosely correlated
+3.03%
RXRX - EDIT
47%
Loosely correlated
+0.11%
More

SLDB and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLDB has been loosely correlated with NTLA. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if SLDB jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLDB
1D Price
Change %
SLDB100%
+7.24%
NTLA - SLDB
48%
Loosely correlated
+3.59%
ALLO - SLDB
47%
Loosely correlated
+5.56%
EDIT - SLDB
47%
Loosely correlated
+13.33%
BEAM - SLDB
46%
Loosely correlated
-0.88%
CRSP - SLDB
44%
Loosely correlated
-0.92%
More